Despite limited randomized trials specific to AERD, the consistent improvements in sinonasal outcomes across studies strongly support dupilumab as an effective treatment for AERD patients post-FESS.
Authors Urge Caution with Dupilumab as First-Line Therapy in Patients with Chronic Rhinosinusitis with Nasal Polyposis
Caution should be used when considering biologics such as dupilumab as a first-line therapy for recalcitrant CRSwNP when viable revision surgical alternatives exist.
Biologics For Chronic Rhinosinusitis: How And When To Use Them For The Best Response
Biologics represent a breakthrough for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). But with high non-response rates and other unresolved issues, researchers are exploring how best to put these therapies to work, panelists said in a session at the Triological Society Combined Sections Meeting.
Platelet-to-Lymphocyte Ratio Might Predict Response to Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps
Platelet-to-lymphocyte ratio (PLR) might have a predictive value in patients with chronic rhinosinusitis with nasal polyps in terms of treatment response to dupilumab, particularly PLR above 131.2.
FDA Approves First Treatment for Eosinophilic Esophagitis
In May, the U.S. Food and Drug Administration approved dupilumab (Dupixent) as a treatment for eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least […]